Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

S. M. O'Brien, H. M. Kantarjian, J. Cortes, M. Beran, C. A. Koller, F. J. Giles, S. Lerner, M. Keating

Research output: Contribution to journalArticle

Abstract

Purpose: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro synergistic activity of the two agents. Patients and Methods: A total of 128 patients with CLL were treated with fludarabine 30 mg/m2 intravenously daily for 3 days and cyclophosphamide at either 500 mg/m2 daily for 3 days (n = 11), 350 mg/m2/d for 3 days (n = 26), or 300 mg/m2 daily for 3 days (n = 91). The cyclophosphamide dose was decreased because of myelosuppression in the early part of the study. Patients were divided into four groups based on the expectation for response to single-agent fludarabine, including previously untreated patients, patients previously treated with alkylating agents, patients successfully treated with alkylating agents and fludarabine but relapsing, and patients refractory to fludarabine with or without alkylating agents. Results: Fludarabine and cyclophosphamide produced ≥ 80% response rates in all patients not refractory to fludarabine at the start of therapy as well as a 38% response rate in patients who were refractory to fludarabine. The complete remission (CR) rate was 35% in previously untreated patients, which was not significantly different from the CR rate in historical control patients treated with single-agent fludarabine. However, residual disease assessed by flow cytometry occurred in only 8% of previously untreated patients achieving CR, and median time to progression has not been reached after a median follow-up of 41 months. The main complication of therapy was related to myelosuppression and infection. Neutropenia to less than 500 × 109/L was noted in 48% of patients who received cyclophosphamide 300 mg/m2. Pneumonia or sepsis occurred in 25% of patients, and fever of unknown origin occurred in another 25%. Pneumonia or sepsis were significantly more frequent in patients who were refractory to fludarabine at the start of combination chemotherapy. Conclusion: Fludarabine and cyclophosphamide seem to have a significant advantage over single-agent fludarabine in the salvage setting. Although the CR rate was not increased in previously untreated patients, residual disease detected by flow cytometry was rare and remission durations seemed to be prolonged in this subset. Myelosuppression and infection remain the most significant complications of therapy in CLL.

Original languageEnglish (US)
Pages (from-to)1414-1420
Number of pages7
JournalJournal of Clinical Oncology
Volume19
Issue number5
DOIs
StatePublished - Mar 1 2001
Externally publishedYes

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cyclophosphamide
Alkylating Agents
fludarabine
Sepsis
Pneumonia
Flow Cytometry
Fever of Unknown Origin
Therapeutics
Infection
Combination Drug Therapy
Neutropenia

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

O'Brien, S. M., Kantarjian, H. M., Cortes, J., Beran, M., Koller, C. A., Giles, F. J., ... Keating, M. (2001). Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. Journal of Clinical Oncology, 19(5), 1414-1420. https://doi.org/10.1200/JCO.2001.19.5.1414

Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. / O'Brien, S. M.; Kantarjian, H. M.; Cortes, J.; Beran, M.; Koller, C. A.; Giles, F. J.; Lerner, S.; Keating, M.

In: Journal of Clinical Oncology, Vol. 19, No. 5, 01.03.2001, p. 1414-1420.

Research output: Contribution to journalArticle

O'Brien, SM, Kantarjian, HM, Cortes, J, Beran, M, Koller, CA, Giles, FJ, Lerner, S & Keating, M 2001, 'Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia', Journal of Clinical Oncology, vol. 19, no. 5, pp. 1414-1420. https://doi.org/10.1200/JCO.2001.19.5.1414
O'Brien, S. M. ; Kantarjian, H. M. ; Cortes, J. ; Beran, M. ; Koller, C. A. ; Giles, F. J. ; Lerner, S. ; Keating, M. / Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 5. pp. 1414-1420.
@article{2c9c23778c8f4b5ead169d0ae859d85d,
title = "Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia",
abstract = "Purpose: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro synergistic activity of the two agents. Patients and Methods: A total of 128 patients with CLL were treated with fludarabine 30 mg/m2 intravenously daily for 3 days and cyclophosphamide at either 500 mg/m2 daily for 3 days (n = 11), 350 mg/m2/d for 3 days (n = 26), or 300 mg/m2 daily for 3 days (n = 91). The cyclophosphamide dose was decreased because of myelosuppression in the early part of the study. Patients were divided into four groups based on the expectation for response to single-agent fludarabine, including previously untreated patients, patients previously treated with alkylating agents, patients successfully treated with alkylating agents and fludarabine but relapsing, and patients refractory to fludarabine with or without alkylating agents. Results: Fludarabine and cyclophosphamide produced ≥ 80{\%} response rates in all patients not refractory to fludarabine at the start of therapy as well as a 38{\%} response rate in patients who were refractory to fludarabine. The complete remission (CR) rate was 35{\%} in previously untreated patients, which was not significantly different from the CR rate in historical control patients treated with single-agent fludarabine. However, residual disease assessed by flow cytometry occurred in only 8{\%} of previously untreated patients achieving CR, and median time to progression has not been reached after a median follow-up of 41 months. The main complication of therapy was related to myelosuppression and infection. Neutropenia to less than 500 × 109/L was noted in 48{\%} of patients who received cyclophosphamide 300 mg/m2. Pneumonia or sepsis occurred in 25{\%} of patients, and fever of unknown origin occurred in another 25{\%}. Pneumonia or sepsis were significantly more frequent in patients who were refractory to fludarabine at the start of combination chemotherapy. Conclusion: Fludarabine and cyclophosphamide seem to have a significant advantage over single-agent fludarabine in the salvage setting. Although the CR rate was not increased in previously untreated patients, residual disease detected by flow cytometry was rare and remission durations seemed to be prolonged in this subset. Myelosuppression and infection remain the most significant complications of therapy in CLL.",
author = "O'Brien, {S. M.} and Kantarjian, {H. M.} and J. Cortes and M. Beran and Koller, {C. A.} and Giles, {F. J.} and S. Lerner and M. Keating",
year = "2001",
month = "3",
day = "1",
doi = "10.1200/JCO.2001.19.5.1414",
language = "English (US)",
volume = "19",
pages = "1414--1420",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "5",

}

TY - JOUR

T1 - Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia

AU - O'Brien, S. M.

AU - Kantarjian, H. M.

AU - Cortes, J.

AU - Beran, M.

AU - Koller, C. A.

AU - Giles, F. J.

AU - Lerner, S.

AU - Keating, M.

PY - 2001/3/1

Y1 - 2001/3/1

N2 - Purpose: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro synergistic activity of the two agents. Patients and Methods: A total of 128 patients with CLL were treated with fludarabine 30 mg/m2 intravenously daily for 3 days and cyclophosphamide at either 500 mg/m2 daily for 3 days (n = 11), 350 mg/m2/d for 3 days (n = 26), or 300 mg/m2 daily for 3 days (n = 91). The cyclophosphamide dose was decreased because of myelosuppression in the early part of the study. Patients were divided into four groups based on the expectation for response to single-agent fludarabine, including previously untreated patients, patients previously treated with alkylating agents, patients successfully treated with alkylating agents and fludarabine but relapsing, and patients refractory to fludarabine with or without alkylating agents. Results: Fludarabine and cyclophosphamide produced ≥ 80% response rates in all patients not refractory to fludarabine at the start of therapy as well as a 38% response rate in patients who were refractory to fludarabine. The complete remission (CR) rate was 35% in previously untreated patients, which was not significantly different from the CR rate in historical control patients treated with single-agent fludarabine. However, residual disease assessed by flow cytometry occurred in only 8% of previously untreated patients achieving CR, and median time to progression has not been reached after a median follow-up of 41 months. The main complication of therapy was related to myelosuppression and infection. Neutropenia to less than 500 × 109/L was noted in 48% of patients who received cyclophosphamide 300 mg/m2. Pneumonia or sepsis occurred in 25% of patients, and fever of unknown origin occurred in another 25%. Pneumonia or sepsis were significantly more frequent in patients who were refractory to fludarabine at the start of combination chemotherapy. Conclusion: Fludarabine and cyclophosphamide seem to have a significant advantage over single-agent fludarabine in the salvage setting. Although the CR rate was not increased in previously untreated patients, residual disease detected by flow cytometry was rare and remission durations seemed to be prolonged in this subset. Myelosuppression and infection remain the most significant complications of therapy in CLL.

AB - Purpose: To assess the efficacy of combination therapy with fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia (CLL) based on data suggesting in vitro synergistic activity of the two agents. Patients and Methods: A total of 128 patients with CLL were treated with fludarabine 30 mg/m2 intravenously daily for 3 days and cyclophosphamide at either 500 mg/m2 daily for 3 days (n = 11), 350 mg/m2/d for 3 days (n = 26), or 300 mg/m2 daily for 3 days (n = 91). The cyclophosphamide dose was decreased because of myelosuppression in the early part of the study. Patients were divided into four groups based on the expectation for response to single-agent fludarabine, including previously untreated patients, patients previously treated with alkylating agents, patients successfully treated with alkylating agents and fludarabine but relapsing, and patients refractory to fludarabine with or without alkylating agents. Results: Fludarabine and cyclophosphamide produced ≥ 80% response rates in all patients not refractory to fludarabine at the start of therapy as well as a 38% response rate in patients who were refractory to fludarabine. The complete remission (CR) rate was 35% in previously untreated patients, which was not significantly different from the CR rate in historical control patients treated with single-agent fludarabine. However, residual disease assessed by flow cytometry occurred in only 8% of previously untreated patients achieving CR, and median time to progression has not been reached after a median follow-up of 41 months. The main complication of therapy was related to myelosuppression and infection. Neutropenia to less than 500 × 109/L was noted in 48% of patients who received cyclophosphamide 300 mg/m2. Pneumonia or sepsis occurred in 25% of patients, and fever of unknown origin occurred in another 25%. Pneumonia or sepsis were significantly more frequent in patients who were refractory to fludarabine at the start of combination chemotherapy. Conclusion: Fludarabine and cyclophosphamide seem to have a significant advantage over single-agent fludarabine in the salvage setting. Although the CR rate was not increased in previously untreated patients, residual disease detected by flow cytometry was rare and remission durations seemed to be prolonged in this subset. Myelosuppression and infection remain the most significant complications of therapy in CLL.

UR - http://www.scopus.com/inward/record.url?scp=0035282055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035282055&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.5.1414

DO - 10.1200/JCO.2001.19.5.1414

M3 - Article

C2 - 11230486

AN - SCOPUS:0035282055

VL - 19

SP - 1414

EP - 1420

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 5

ER -